{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:33:39Z","timestamp":1793183619309,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK13593701A1"],"award-info":[{"award-number":["R01DK13593701A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U01DP006745-01"],"award-info":[{"award-number":["U01DP006745-01"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI155696"],"award-info":[{"award-number":["R01AI155696"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG3 TR003355"],"award-info":[{"award-number":["UG3 TR003355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cgh.2024.12.007","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T19:09:43Z","timestamp":1735240183000},"page":"2102-2114.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists"],"prefix":"10.1016","volume":"23","author":[{"given":"Han Hee","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Solitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Syal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigid S.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradipta","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-7269","authenticated-orcid":false,"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2024.12.007_bib1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","volume":"23","author":"Fudman","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.12.007_bib2","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib4","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.12.007_bib5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cgh.2018.05.026","article-title":"Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases","volume":"17","author":"Feagan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.12.007_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib7","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2024.12.007_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.cgh.2024.12.007_bib9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2024.12.007_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2024.12.007_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib12","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2024.12.007_bib13","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.12.007_bib14","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib15","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib16","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.12.007_bib18","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(24)00910-7","article-title":"The efficacy and safety of guselkumab as maintenance therapy in patients with moderate to severely active ulcerative colitis: REsults from the Phase 3 Quasar Maintenace study","volume":"166","author":"Rubin","year":"2024","journal-title":"Gastroenterol"},{"key":"10.1016\/j.cgh.2024.12.007_bib19","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.12.007_bib20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2024.12.007_bib21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib22","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.12.007_bib23","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.12.007_bib24","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.12.007_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/17474124.2020.1772057","article-title":"Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach","volume":"14","author":"D'Amico","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.12.007_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib27","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.17305","article-title":"Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"57","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.12.007_bib28","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/ibd\/izad165","article-title":"1-Year comparison of clinical and endoscopic outcomes of tofacitinib vs vedolizumab for ulcerative colitis after anti-tumor necrosis factor failure: a real-world cohort study in the United States","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.12.007_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","article-title":"Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF-experienced ulcerative colitis patients: a nationwide Dutch registry study","volume":"21","author":"Straatmijer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.12.007_bib30","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase iii, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2024.12.007_bib31","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2024.12.007_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cell.2015.08.030","article-title":"Microbiota-dependent sequelae of acute infection compromise tissue-specific immunity","volume":"163","author":"Fonseca","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.cgh.2024.12.007_bib33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41586-023-06968-8","article-title":"Smoking changes adaptive immunity with persistent effects","volume":"626","author":"Saint-Andre","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2024.12.007_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L","article-title":"Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis","volume":"43","author":"Taylor","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2024.12.007_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MIB.0b013e31828100a4","article-title":"Effect of tumor necrosis factor-alpha blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease","volume":"19","author":"Biancheri","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.12.007_bib36","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","article-title":"Optimizing anti-TNF treatment in inflammatory bowel disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.12.007_bib37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.mehy.2008.10.039","article-title":"Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology","volume":"73","author":"Csoka","year":"2009","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.cgh.2024.12.007_bib38","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.molmed.2013.08.006","article-title":"Common non-epigenetic drugs as epigenetic modulators","volume":"19","author":"Lotsch","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.cgh.2024.12.007_bib39","doi-asserted-by":"crossref","unstructured":"Sinha S, McLaren E, Mullick M, et al. FORWARD: a learning framework for logical network perturbations to prioritize targets for drug development. bioRxiv 602603. https:\/\/doi.org\/10.1101\/2024.07.16.602603","DOI":"10.1101\/2024.07.16.602603"},{"key":"10.1016\/j.cgh.2024.12.007_bib40","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2024.12.007_bib41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2019.06.008","article-title":"Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment","volume":"51","author":"Eftychi","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cgh.2024.12.007_bib42","doi-asserted-by":"crossref","first-page":"13806","DOI":"10.1073\/pnas.95.23.13806","article-title":"Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor","volume":"95","author":"Hodge-Dufour","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2024.12.007_bib43","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.4049\/jimmunol.164.4.1722","article-title":"Inhibition of IL-12 production in human monocyte-derived macrophages by TNF","volume":"164","author":"Ma","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2024.12.007_bib44","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/MIB.0000000000001144","article-title":"Clinical outcomes of golimumab as first, second or third Anti-TNF agent in patients with moderate-to-severe ulcerative colitis","volume":"23","author":"Taxonera","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.12.007_bib45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2036.2012.05214.x","article-title":"Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease","volume":"36","author":"de Silva","year":"2012","journal-title":"Aliment Pharmacol Ther"}],"updated-by":[{"DOI":"10.1016\/j.cgh.2026.01.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000}},{"DOI":"10.1016\/j.cgh.2026.01.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000}}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524011327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524011327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:41:28Z","timestamp":1777966888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524011327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1542356524011327"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2024.12.007","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute","name":"copyright","label":"Copyright"}]}}